相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line
Magdalena Kusaczuk et al.
TUMOR BIOLOGY (2016)
Phenylbutyric Acid: Simple Structure - Multiple Effects
Magdalena Kusaczuk et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Glucose-regulated protein 94 is a novel glioma biomarker and promotes the aggressiveness of glioma via Wnt/β-catenin signaling pathway
Tieyi Hu et al.
TUMOR BIOLOGY (2015)
Growth Inhibition of Pancreatic Cancer Cells by Histone Deacetylase Inhibitor Belinostat Through Suppression of Multiple Pathways Including HIF, NFkB, and mTOR Signaling In Vitro and In Vivo
Wenwen Chien et al.
MOLECULAR CARCINOGENESIS (2014)
Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe
M. Cornago et al.
CELL DEATH & DISEASE (2014)
Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells
Akinori Sato et al.
BMC UROLOGY (2014)
Molecular Chaperone ORP150 in ER Stress-related Diseases
Magdalena Kusaczuk et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
Daniel Chan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment
Shu-Fu Lin et al.
PLOS ONE (2013)
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
Amanda Cashen et al.
ANNALS OF HEMATOLOGY (2012)
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
Dmitriy I. Dovzhanskiy et al.
BMC CANCER (2012)
Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response
Soumen Kahali et al.
FASEB JOURNAL (2012)
1H NMR Metabolomics Analysis of Glioblastoma Subtypes CORRELATION BETWEEN METABOLOMICS AND GENE EXPRESSION CHARACTERISTICS
Miroslava Cuperlovic-Culf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells
Feng-Ming Wang et al.
EXPERIMENTAL HEMATOLOGY (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
Nonhistone protein acetylation as cancer therapy targets
Brahma N. Singh et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells
Rekha Rao et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Activation of the Unfolded Protein Response Contributes toward the Antitumor Activity of Vorinostat
Soumen Kahali et al.
NEOPLASIA (2010)
Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts
Anne Monks et al.
ANTI-CANCER DRUGS (2009)
Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin
KetLi Ho et al.
CANCER EPIDEMIOLOGY (2009)
Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor
Peter Gimsing
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay
Jin C. Kim et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA Microarray
Dong Yin et al.
MOLECULAR CANCER RESEARCH (2009)
Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis
Peter Baumeister et al.
MOLECULAR CANCER THERAPEUTICS (2009)
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
Peter Gimsing et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis
Hae Kyung Lee et al.
NEURO-ONCOLOGY (2008)
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
Xiaozhong Qian et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
Michael T. Buckley et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
A novel apoptosis pathway activated by the carboxyl terminus of p21
C Dong et al.
BLOOD (2005)
Histone acetylation may suppress human glioma cell proliferation when p21WAF/Cip1 and gelsolin are induced
H Kamitani et al.
NEURO-ONCOLOGY (2002)
A new mathematical model for relative quantification in real-time RT-PCR
MW Pfaffl
NUCLEIC ACIDS RESEARCH (2001)
分享论文
